You searched for: abrupt (Engelska - Maltesiska)

abrupt discontinuation should be avoided.
twaqqifi tal- kura għandha jiġi evitat twaqqif f’ salt.

bradycardiab (following abrupt discontinuation of therapy)
bradikardijab (wara waqfien f'daqqa tal-kura)

discontinuation of treatment abrupt discontinuation should be avoided.
sospensjoni tal- kura għandha tiġi evitata sospensjoni f’ daqqa waħda.

there is limited experience with abrupt discontinuation of tracleer.
hemm esperjenza limitata dwar it- twaqqif f’ daqqa tal- kura bi tracleer.

the cross-section must not exhibit any abrupt alteration.
il-cross-section ma għandha turi ebda bidla f'daqqa.

there is limited experience with abrupt discontinuation of sitaxentan sodium.
hemm esperjenza limitata dwar il-waqfien f’daqqa ta’ sitaxentan sodium.

an abrupt discontinuation of the current national systems poses real risks.
l-abbandun f’salt tas-sistemi nazzjonali attwali jinvolvi riskji reali.

abrupt discontinuation of corticosteroids after initiation of nucala therapy is not recommended.
it-twaqqif tal-kortikosterojdi f’daqqa wara li tinbeda t-terapija b’nucala mhuwiex rakkomandat.

however, intensification of insulin therapy with abrupt improvement in glycaemic control may be
madankollu, l- intensifikar tat- terapija bl- insulina biex il- livell taz- zokkor fid- demm ikun ikkontrollat f’ daqqa, jista ’ jġib miegħu aggravament temporanju tar- retinopatija tad- dijabete.

abrupt discontinuation of dopaminergic therapy can lead to the development of a neuroleptic malignant syndrome.
it-twaqqif f’daqqa tat-terapija dopaminerġika jista’ jwassal għall-iżvilupp tas-sindrome malinn newroleptiku.

discontinuation of venlafaxine (particularly when abrupt) commonly leads to withdrawal symptoms.
30 it- twaqqif ta ’ venlafaxine (partikularment meta jsir f’ daqqa) ġeneralment iwassal għal sintomi ta ’ meta tieqaf tieħu l- mediċina.

once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms.
la darba d -

rebound (worsening of symptoms after abrupt discontinuation of treatment) can not be excluded.
ir - rebound (sintomi li jmorru għall- agħar wara t- twaqqif f’ daqqa tal- kura) ma tistax tkun eskluża.

abrupt discontinuation of lisinopril treatment is not associated with any substantial rebound effect (blood pressure elevation).
twaqqif f’ daqqa tat- trattament b’ lisinopril mhux assoċjat ma ’ xi effett sostanzjali ta ’ rebound (pressjoni tad- demm li togħla).

symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see section 4.2)
sintomi li jissuġerixxu sindromu newrolettiku mallinn kienu rapportati mat- twaqqif f’ daqqa tat- terapija dopaminerġika (ara sezzjoni 4. 2).

withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8).
is- sintomi ta ’ meta tieqaf tieħu l- mediċina, meta titwaqqaf il- kura, huma komuni, partikularment jekk it- twaqqif isir f’ daqqa (ara sezzjoni 4. 8).

neuroleptic malignant syndrome symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see section 4.2).
sindrome malinn newroleptiku sintomi li jissuġġerixxu sindrome malinn newroleptiku kienu rrappurtati mat- twaqqif f’ daqqa tat - terapija dopaminerġika (ara sezzjoni 4. 2).